Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Lymphomas
  Follow Topic   Edit Search
Your search returned 8 results
from the time period: last 30 days.
Sort by Relevance / Date Group By Journal / No Grouping
JAMA 
AbstractText: An increased risk of lymphoma has been reported among patients receiving thiopurines for inflammatory bowel ... The risk of lymphoma associated with anti-tumor necrosis factor (TNF) agents either alone ... with thiopurines is uncertain AbstractText: To assess the risk of lymphoma associated with thiopurines and anti-TNF agents, used alone or ...
Lymphoma (8), Necrosis (2), Inflammatory Bowel Diseases (2), more mentions
Lancet (London, England) 
... doses) is very active in patients with advanced-stage Hodgkin's lymphoma, albeit at the expense of severe toxicities... aged 18-60 years with newly diagnosed, advanced-stage Hodgkin's lymphoma in 301 hospitals and private practices in Germany, Switzerland, Austria ... 2-guided treatment strategy for patients with advanced-stage Hodgkin's lymphoma AbstractText: Deutsche Krebshilfe, Swiss State Secretariat for Education and Research ...
Hodgkin Disease (3), Lymphoma (1), Infections (1), more mentions
The Lancet. Oncology 
AbstractText: A high proportion of patients with relapsed classical Hodgkin's lymphoma achieve a response with the antibody-drug conjugate brentuximab vedotin ... aged 18-60 years) with newly diagnosed, advanced, classical Hodgkin's lymphoma were randomly assigned (1:1) to treatment with six cycles ... challenge standard eBEACOPP for the treatment of advanced classical Hodgkin's lymphoma in the phase 3 HD21 study by the German Hodgkin ...
Hodgkin Disease (4), Peripheral Nervous System Diseases (2), Infections (1), more mentions
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
... maintenance as initial therapy for patients with advanced-stage follicular lymphoma (FL... risk of dying as a result of causes unrelated to lymphoma progression with R-FM versus R-CVP... initially treated with R-CVP had a higher risk of lymphoma progression compared with those receiving R-CHOP, as well as ...
Lymphoma (2), Follicular Lymphoma (2), more mentions
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
Abstract: Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavior. We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma. Here, we assess EFS24 and subsequent overall survival (OS) in large, multinational PTCL cohorts.
T-Cell Lymphomas (2), Diffuse Large B-Cell Lymphoma (1), more mentions
Blood 
Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement..
Diffuse Large B-Cell Lymphoma (2), more mentions
Cancers 
Abstract: Targeting anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase receptor initially identified as a potent oncogenic driver in anaplastic large-cell lymphoma (ALCL) in the form of nucleophosmin (NPM)-ALK fusion protein, using tyrosine kinase inhibitors has shown to be a promising therapeutic approach for ... Keyword: anaplastic lymphoma kinase.
Oncology (2)
Lymphoma (3), Neoplasms (3), Anaplastic Large-Cell Lymphoma (1), more mentions
Blood 
Abstract: The benefit of radiotherapy (RT) following chemotherapy in limited-stage diffuse large B-cell lymphoma (DLBCL) remains controversial. Before the Rituximab (R) era, randomized trials have reported conflicting results. We conducted a randomized trial in patients with non-bulky (tumor size 60 yrs) and disease stage (I/II. The patients received 4 or 6 consecutive cycles of R-CHOP ...
Diffuse Large B-Cell Lymphoma (2), Neoplasms (1), more mentions